Gyre Therapeutics, Inc. Debt Securities, Available-for-sale, Current
Gyre Therapeutics, Inc. (GYRE) had Debt Securities, Available-for-sale, Current of $0 as of 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Short-Term Investments
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent · last filed 2023-03-30
- 2022-12-31: Debt Securities, Available-for-sale, Current $0.00.
- 2022-09-30: Debt Securities, Available-for-sale, Current $0.00.
- 2022-06-30: Debt Securities, Available-for-sale, Current $0.00.
- 2022-03-31: Debt Securities, Available-for-sale, Current $0.00.
| Period end | Debt Securities, Available-for-sale, Current |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-30 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-15 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-09 |
| 2021-12-31 | $2.50M 10-K · filed 2022-03-31 |
| 2021-09-30 | $5.40M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $12.90M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $24.00M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $49.00M 10-K · filed 2021-03-04 |
| 2020-09-30 | $78.00M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |